Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
02/2012
02/16/2012WO2011143383A9 Protease catalyzed in situ end capping of oligopeptides in aqueous media
02/16/2012WO2011141824A9 Methods for identifying nmda receptor modulators
02/16/2012WO2011138762A3 Cholesterol ester for reducing cholesterol absorption
02/16/2012WO2011126833A3 Anti-inflammatory factors
02/16/2012WO2011115688A3 Integrin interaction inhibitors for the treatment of cancer
02/16/2012WO2011091419A3 Recombinant derivatives of botulinum neurotoxins engineered for trafficking studies and neuronal delivery
02/16/2012WO2011051457A3 Purified emd protein composition
02/16/2012WO2011044089A3 Methods of treating depression and other related diseases
02/16/2012WO2011004148A8 Methods related to a mutation in complement factor h-related protein 5 in patients with glomerulonephritis
02/16/2012WO2005110456A8 T-cell death-inducing epitopes
02/16/2012WO2002085309A9 Composition, formulations & kits for treatment of respiratory & lung disease with anti-sense oligonucleotides & a bronchodilating agent
02/16/2012US20120042400 Rtd receptor
02/16/2012US20120042051 System and Method for Monitoring and Analyzing Internet Traffic
02/16/2012US20120041357 Method of controlled drug release from a liposome carrier
02/16/2012US20120041176 Ucp4
02/16/2012US20120041067 Methods of Inducing Terminal Differentiation
02/16/2012US20120041053 DELIVERY OF dsRNA TO ARTHROPODS
02/16/2012US20120041010 Pharmaceutical combination of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3r,5s)-3,5-dihydroxyhept-6-enoic acid and candesartan
02/16/2012US20120040918 Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid
02/16/2012US20120040917 Splice Switching Oligomers for TNF Superfamily Receptors and Their Use in Treatment of Disease
02/16/2012US20120040916 Molecular inhibitors of the wnt/beta-catenin pathway
02/16/2012US20120040915 Peptides and nanoparticles for therapeutic and diagnostic applications
02/16/2012US20120040914 Enhancing effectiveness of glial cancer therapies
02/16/2012US20120040913 Methods and compositions for treating diabetes
02/16/2012US20120040911 Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
02/16/2012US20120040910 Methods of preventing or treating brain diseases
02/16/2012US20120040909 Identification of novel antagonist toxins of t-type calcium channel for analgesic purposes
02/16/2012US20120040908 Fracture repair promoter
02/16/2012US20120040907 Method of Use of Bioactive Materials
02/16/2012US20120040906 Protein targets in disease
02/16/2012US20120040905 Means for purifying a coagulation protein, and methods for implementing same
02/16/2012US20120040904 Boronate Medicaments for Preventing Thrombosis During Surgery
02/16/2012US20120040903 Method for treating dyspnea associated with acute heart failure
02/16/2012US20120040902 Method of treating dyspnea associated with acute heart failure
02/16/2012US20120040901 Novel biomaterials, their preparation and use
02/16/2012US20120040900 Compositions of and methods of using ligand dimers
02/16/2012US20120040899 Method for Treating Hyperglycemia with GLP-1
02/16/2012US20120040898 Pharmaceutical compositions
02/16/2012US20120040897 Novel derivatives of acyl cyanopyrrolidines
02/16/2012US20120040896 Compositions, methods and uses for modulation of brca 1
02/16/2012US20120040895 Peptide availability
02/16/2012US20120040894 Mini-Hepcidin Peptides and Methods of Using thereof
02/16/2012US20120040893 Modification of feeding behaviour
02/16/2012US20120040892 Methods and Compositions for the Treatment of Heart Failure and Other Disorders
02/16/2012US20120040891 Hiv fusion inhibitor peptides with improved biological properties
02/16/2012US20120040890 Inhibitor of the uracil-dna glycosylase enzyme and uses thereof
02/16/2012US20120040889 Peptidomimetic macrocycles
02/16/2012US20120040888 Anti-infective hydroxy-phenyl-benzoates and methods of use
02/16/2012US20120040887 Composition for the treatment of osteomyelitis, method for preparing the same, and method for the treatment of osteomyelitis
02/16/2012US20120040886 Analogues of Neuropeptide Y Having Proline Substitution At Position 34
02/16/2012US20120040885 Analogues of Neuropeptide Y Having At Least One Synthetic Amino Acid Substitution
02/16/2012US20120040884 Methods and Reagents for Treatment and Diagnosis of Vascular Disorders and Age-Related Macular Degeneration
02/16/2012US20120040829 Bacterial ghosts as carrier and targeting vehicles
02/16/2012US20120040033 Anti-infective mangrove extract against viruses, bacteria and fungi
02/16/2012US20120040025 Compositions and Methods for Treating Disorders Associated with Salt or Fluid Retention
02/16/2012US20120040021 Methods and compositions for the treatment of cancer
02/16/2012US20120040020 Compounds useful as inhibitors of atr kinase
02/16/2012US20120040012 Therapeutic stem cell nutrient composition and uses thereof
02/16/2012US20120040000 Peptide pharmaceutical for oral delivery
02/16/2012US20120039991 Use of apoptosis inhibiting compounds in degenerative neurological disorders
02/16/2012US20120039989 Erythrocyte-binding therapeutics
02/16/2012US20120039988 Cancer-targeting peptides and uses thereof in cancer therapy
02/16/2012US20120039985 Dendritic cell modulation in post-ischemic wounds
02/16/2012US20120039980 Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
02/16/2012US20120039978 Novel Anti-Viral Method
02/16/2012US20120039958 Compositions and methods for treatment of taupathy
02/16/2012US20120039956 Dry storage stabilizing composition for biological materials
02/16/2012US20120039949 Stable Solid Formulations of GC-C Receptor Agonist Polypeptides Suitable for Oral Administration
02/16/2012US20120039944 Whey and thymus function
02/16/2012US20120039940 Methods for treating uterine disorders
02/16/2012US20120039924 Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
02/16/2012US20120039923 Modified HIV-1 Envelope Proteins
02/16/2012US20120039922 Method and peptide for regulating cellular activity
02/16/2012US20120039914 Methods and compositions for using mhc class ii invariant chain polypeptides as a receptor for macrophage migration inhibitory factor
02/16/2012US20120039908 Control of Protein Glycosylation and Compositions and Methods Relating Thereto
02/16/2012US20120039902 Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo
02/16/2012US20120039890 Methods of treatment using antibodies to neutrokine-alpha
02/16/2012US20120039888 Methods Of Inhibiting Inflammation-Associated Tissue Damage By Inhibiting Neutrophil Activity
02/16/2012US20120039883 Detection and diagnosis of inflammatory disorders
02/16/2012US20120039881 Compositions and methods for treating neurological disorders
02/16/2012US20120039874 Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof
02/16/2012US20120039872 Il-3 inhibitors in use for treatment of rheumatoid arthritis in an early stage
02/16/2012US20120039868 Biomarkers for Graft Rejection
02/16/2012US20120039867 Immune System Function in Conditions Characterized by Elevated Double Strand Breaks
02/16/2012US20120039865 Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
02/16/2012US20120039863 Recombinant factor x with no glycosylation and method for preparing the same
02/16/2012US20120039862 Extended Length Botulinum Toxin Formulation for Human or Mammalian Use
02/16/2012US20120039861 Identification of extracellular form of pten that can be used to treat tumors
02/16/2012US20120039850 HCV Combination Therapies Comprising Pegylated Interferon, Ribavirin and Telaprevir
02/16/2012US20120039849 Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase
02/16/2012US20120039848 Hepatitis c virus inhibitors
02/16/2012US20120039847 Hepatitis C Virus Inhibitors
02/16/2012US20120039846 Hepatitis c antibodies and uses thereof
02/16/2012US20120039845 Nucleoside prodrugs and uses thereof
02/16/2012US20120039844 Composition and use of n-alpha-methylhistamine dihydrochloride for the reduction of oxygen radical formation
02/16/2012US20120039843 Conjugates of a polypeptide and an oligosaccharide
02/16/2012US20120039842 Compositions and methods that enhance an immune response
02/16/2012US20120039841 T-Helper Cell Type 17 Lineage-Specific Adjuvants, Compositions and Methods
02/16/2012US20120039840 Use of IL-27-P28 to antagonize IL-6 mediated signaling
02/16/2012US20120039839 Hypoxia Induced Mitogenic Factor
1 ... 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 ... 3163